A skin cream for peripheral neuropathy? Small molecule may go a long way

by Nancy Fliesler on January 29, 2014

The footpads of diabetic mice (line-D) treated with a cream containing XIB4035 have increased numbers of nerve terminals (shown in green in the lower right panel), whereas mice given a control cream (lower left) do not. The top two panels represent healthy “wild type” mice.

The footpads of diabetic mice given a cream containing XIB4035 (lower right) have new nerve terminals (shown in green), whereas mice given a control cream (lower left) do not. The top two panels represent healthy “wild type” mice.

About half of people with diabetes develop peripheral neuropathy. The most common form, small-fiber neuropathy, generally starts in the feet, causing pain, odd sensations like pricks and “pins and needles,” and—the most worrisome feature—a loss of sensation that can increase the chance of ulcers and infections.

In some cases, that may lead to the need for amputation—as happened with my diabetic great-grandfather whose numbed feet, unbeknownst to him, got too close to the fire.

While there are some treatments to reduce pain, there’s nothing that restores sensation. Nor do any existing treatments address the underlying cause of the neuropathy: the degeneration or dysfunction of the endings of the sensory neurons in the skin.

Gabriel Corfas, PhD, of the F.M. Kirby Neurobiology Center at Boston Children’s Hospital, wondered if replenishing a growth factor called GDNF (short for glial-derived neurotrophic factor) could improve sensory neurons’ health and function. Other investigators have been testing this, but because GDNF is a large molecule, it’s hard to deliver. “The only way to get it into the nervous system is through invasive methods such as injections into the spinal cord,” says Corfas.

Because the sensory nerve endings are in the skin, Corfas felt it might be possible to treat neuropathy topically, a gentler treatment that would avoid the side effects of systemic treatments. He turned not to GDNF, which is too large to be absorbed through the skin, but to a small-molecule compound called XIB4035 that enhances GDNF’s effects—making the little that’s there go a longer way.

“When you use an enhancer, you need less GDNF to activate receptors on the sensory neuron,” Corfas explains. “The receptors are activated for longer, and GDNF’s effects are stronger.”

In last week’s edition of the Proceedings of the National Academy of Sciences, his team reports good results with a skin cream laced with XIB4035 in two mouse models of small-fiber neuropathy.

Gabriel Corfas

Corfas

As compared with controls given an inactive cream, mice given the XIB4035 skin cream showed improvements in nerve structure and regained sensitivity to heat (much more quickly removing their paws from a hot plate). Sensation improved in both diabetic mice and mice that developed small-fiber neuropathy through genetic manipulation. Even mice with advanced disease showed improvements.

The study offers hope for a more targeted, practical treatment for small-fiber neuropathy, says Corfas. “By giving an enhancer, you help only the cells that are naturally exposed to the growth factors and have the receptors for them,” he says. “Also, because the enhancer is given topically, we are effectively putting it directly into the neurons, which have their endings in the skin. So there is very little systemic exposure, and we believe there will be far fewer side effects.”

The team is now examining whether the cream has any value for large-fiber neuropathy, which involves motor fibers and is often caused by injury. They also will further explore skin absorption of XIB4035, as well as the effects of systemic delivery.

The cream is still experimental, Corfas cautions, and years away from human testing. He elaborates on the cream in this Q&A with Boston Children’s Technology & Innovation Development Office (TIDO), which provided financial support for the project. For information on business opportunities, read more on TIDO’s website or contact connie.caron@childrens.harvard.edu.

5 comments

  • En kar…

    Hi! Can this work as with Lyme? After the infection of course… I can participate in trial! :)

    • nansona

      This work is still in an early stage, and likely to be years away from any clinical trial (but thanks for the kind offer). According to Dr. Corfas, there are theoretical reasons why to think it might work with Lyme, since it induces small-fiber neuropathy. But that would need to be tested. –Nancy Fliesler

      • En kar…

        Thank you very much for the answer! :) Hope it will go faster than you predict! :) It will be a “sensation” if it works! Help a lot of people. But if the nerve endings grow. How will it stop growing? And, what do the cream do for the scarring? How does it work? …or how is it supposed to work? If it works, I belive it would be bought in every household where I live. Norway is a “neanderthal”-country when it comes to Lyme, and many are suffering.

  • En kar…

    Large fiber neuropathy? What is in it? If you can move you leg?

  • En kar…

    This research is more than 10 years old.. why are people thinking about it now? No one who are willing to try it? Or what is the deal?

Previous post:

Next post: